Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections

Carvalheiro, Manuela; Esteves, M. Alexandra; Santos-Mateus, David; Lopes, Rodrigo J.G.; Rodrigues, A.; Eleutério, Carla; Scoulica, Effie; Santos‐Gomes, Gabriela; Cruz, M.E.M.

doi:10.1016/j.ejpb.2015.04.018

Cited by 24 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,10 Over the past decades, liposomes have demonstrated an increase in the therapeutic efficacy of several drugs. [11][12][13][14][15][16][17][18] Depending upon their physical properties, liposomes are recognized as foreign particles after in vivo administration and are easily cleared by the reticuloendothelial system that harbors Leishmania parasites. [19][20][21] Thus, the association or incorporation of chemotherapeutic agents in liposomes has immense therapeutic benefits against the intracellular infection of Leishmania.…”

Section: Introductionmentioning

confidence: 99%

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis

Want

Islammudin

Chouhan

et al. 2017

IJN

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis

Want

Islammudin

Chouhan

et al. 2017

IJN

View full text Add to dashboard Cite

“…According to findings ~15,000 people are affected annually in Iran. The real rate of incidence is 4 to 5 times higher than the reported prevalence [10][11][12].…”

Section: Introductionmentioning

confidence: 62%

“…Leishmaniasis is reported from 88 countries and estimated that 350 million world-wide are at risk of acquiring one form of the diseases, and 12 million are infected with annual occurrence rate of about 1.5 to 2 million [8][9][10]. According to findings ~15,000 people are affected annually in Iran.…”

Section: Introductionmentioning

confidence: 99%

Application of Nano Drugs in Treatment of Leishmaniasis

Shahcheraghi¹

2016

Glob J Infect Dis Clin Res

View full text Add to dashboard Cite

Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most common form of leishmaniasis is cutaneous leishmaniasis (CL) with 1.5 million new cases per year. Correct diagnosis and characterization of the particular parasite is important for evaluating prognosis and prescribing appropriate treatment. The current management of leishmaniasis is drug treatment of patients, to alleviate disease and vector control to reduce its transmission. Also, current treatments for visceral leishmaniasis are unsatisfactory because of their toxicity, resistance and high cost. The purpose of the present study was to review the application of nano drugs in treatment of leishmaniasis. Materials and Methods:it was used as source of research the following databases: MEDLINE, Cochrane Library, Scielo, PubMed and the database of CAPES.Results: It has been proved nanosilver particles with highly small sizes, have a good penetration into the cutaneous lesions and a good efficacy on leishmaniasis.anti-leishmanial therapy [14][15][16][17]. Although glucantime is commonly used for the treatment of leishmaniasis, it has some side effects including increased liver enzymes and electrocardiogram changes [17]. In addition, the drug is expensive, the injection is painful, and research shows that resistance of parasite to glucantime is growing in different parts of the world [17][18][19][20]. The use of nanotechnology is ever-expanding in today's technologically advanced world. This form of technology has many advantages over existing ones in many fields and medicine is one of them [20]. There are numerous devices and mechanisms developed with the aid of nanotechnology that can help cure diseases/disorders in a much better and more efficient manner [21]. The usefulness of nanotechnology can especially be seen in the treatment of infectious diseases [21,22]. This review has investigated the treatment of leishmaniasis by nano drugs. Nano drugs against leishmaniasisNanotechnology must be applied for curing infectious disease like leishmaniasis [22]. Many drugs have been made and are still being discovered, but the protozoan re-emerges showing drug resistance to the effective medications [23]. Nanotechnology has just managed to show its promise in developing a liposomal formulation called amphotericin B for leishmaniasis but has serious side effects and is not cost effective in developing countries [23][24][25]. Initial, nanodelivery systems for delivering chemotherapeutics were nanodisks impregnanted with amphotericin B, polymericnanoparticle loaded with pentamidine, primaquine, and niosomes, which still need validation at the clinical level [25][26][27][28]. There is an urgent need to take up assignments to use effective nanotechnology devices in combating this infectious disease [25][26][27][28].Different mechanisms were proposed for antimicrobial property of nanoparticles [28]. One mechanism is binding of nanoparticle to sulfur/ phosphorus-containing biomolecules such as proteins and DNA, which leads to...

show abstract

“…In the treatment of leishmaniosis, an interesting approach is based on the use of dinitroanilines, because of their specific binding to parasite but not human tubulins. However, their low water solubility and instability have blocked their development as antiparasitic agents ( 51 ). Encapsulation of drug by dimyristoyl PC- and dimyristoyl phosphatidylglycerol-based liposomes overcome those limitations and allowed to efficiently deliver the drugs, reaching a therapeutic advantage as demonstrated in animal models ( 51 ).…”

Section: Liposomes As Carrier For Drugsmentioning

confidence: 99%

The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases

et al. 2018

View full text Add to dashboard Cite

Liposomes are closed bilayer structures spontaneously formed by hydrated phospholipids that are widely used as efficient delivery systems for drugs or antigens, due to their capability to encapsulate bioactive hydrophilic, amphipathic, and lipophilic molecules into inner water phase or within lipid leaflets. The efficacy of liposomes as drug or antigen carriers has been improved in the last years to ameliorate pharmacokinetics and capacity to release their cargo in selected target organs or cells. Moreover, different formulations and variations in liposome composition have been often proposed to include immunostimulatory molecules, ligands for specific receptors, or stimuli responsive compounds. Intriguingly, independent research has unveiled the capacity of several phospholipids to play critical roles as intracellular messengers in modulating both innate and adaptive immune responses through various mechanisms, including (i) activation of different antimicrobial enzymatic pathways, (ii) driving the fusion–fission events between endosomes with direct consequences to phagosome maturation and/or to antigen presentation pathway, and (iii) modulation of the inflammatory response. These features can be exploited by including selected bioactive phospholipids in the bilayer scaffold of liposomes. This would represent an important step forward since drug or antigen carrying liposomes could be engineered to simultaneously activate different signal transduction pathways and target specific cells or tissues to induce antigen-specific T and/or B cell response. This lipid-based host-directed strategy can provide a focused antimicrobial innate and adaptive immune response against specific pathogens and offer a novel prophylactic or therapeutic option against chronic, recurrent, or drug-resistant infections.

show abstract

Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections

Cited by 24 publications

References 36 publications

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis

Application of Nano Drugs in Treatment of Leishmaniasis

The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases

Contact Info

Product

Resources

About